Overview

Treatment Response of Injectafer vs Oral Iron to Baseline Hepcidin Levels in Patients With Iron Deficiency Anemia (IDA) Secondary to Inflammatory Bowel Disease (IBD) or Gastric Bypass

Status:
Completed

Trial end date:
2017-10-01

Target enrollment:

Participant gender:

Summary

The primary objective of this study is to evaluate the treatment response of Injectafer vs. oral iron to baseline hepcidin levels to determine if any of these select IBD or Gastric Bypass patients may demonstrate to be inappropriate for oral iron therapy.

Phase:

Phase 4

Details

Lead Sponsor:

American Regent, Inc.
Luitpold Pharmaceuticals

Treatments:

Ferric Compounds
Hepcidins
Iron